SGX:569

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Vicplas International

Executive Summary

Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, and China. More Details


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Vicplas International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 569's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.0%

569

-7.7%

SG Medical Equipment

-1.3%

SG Market


1 Year Return

253.9%

569

374.2%

SG Medical Equipment

-21.4%

SG Market

Return vs Industry: 569 underperformed the SG Medical Equipment industry which returned 404.3% over the past year.

Return vs Market: 569 exceeded the SG Market which returned -21.4% over the past year.


Shareholder returns

569IndustryMarket
7 Day-6.0%-7.7%-1.3%
30 Day1.6%14.3%0.9%
90 Day136.8%24.2%-3.4%
1 Year280.8%253.9%381.1%374.2%-17.1%-21.4%
3 Year253.3%189.0%366.9%339.6%-19.9%-29.6%
5 Year283.1%169.2%257.2%231.1%-6.4%-23.4%

Price Volatility Vs. Market

How volatile is Vicplas International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vicplas International undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 569 (SGD0.32) is trading below our estimate of fair value (SGD0.79)

Significantly Below Fair Value: 569 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 569 is poor value based on its PE Ratio (32x) compared to the XA Medical Equipment industry average (31.8x).

PE vs Market: 569 is poor value based on its PE Ratio (32x) compared to the SG market (13.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 569's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 569 is good value based on its PB Ratio (2.6x) compared to the SG Medical Equipment industry average (6.3x).


Next Steps

Future Growth

How is Vicplas International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vicplas International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vicplas International performed over the past 5 years?

-5.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 569 has a large one-off gain of SGD1.9M impacting its July 31 2020 financial results.

Growing Profit Margin: 569's current net profit margins (5.4%) are higher than last year (5.1%).


Past Earnings Growth Analysis

Earnings Trend: 569's earnings have declined by 5% per year over the past 5 years.

Accelerating Growth: 569's earnings growth over the past year (17.4%) exceeds its 5-year average (-5% per year).

Earnings vs Industry: 569 earnings growth over the past year (17.4%) underperformed the Medical Equipment industry 19.7%.


Return on Equity

High ROE: 569's Return on Equity (7.9%) is considered low.


Next Steps

Financial Health

How is Vicplas International's financial position?


Financial Position Analysis

Short Term Liabilities: 569's short term assets (SGD49.5M) exceed its short term liabilities (SGD23.2M).

Long Term Liabilities: 569's short term assets (SGD49.5M) exceed its long term liabilities (SGD6.2M).


Debt to Equity History and Analysis

Debt Level: 569's debt to equity ratio (14%) is considered satisfactory.

Reducing Debt: 569's debt to equity ratio has increased from 3.7% to 14% over the past 5 years.

Debt Coverage: 569's debt is well covered by operating cash flow (140.2%).

Interest Coverage: 569's interest payments on its debt are well covered by EBIT (9.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Vicplas International current dividend yield, its reliability and sustainability?

1.19%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: 569's dividend (1.19%) isn’t notable compared to the bottom 25% of dividend payers in the SG market (2.44%).

High Dividend: 569's dividend (1.19%) is low compared to the top 25% of dividend payers in the SG market (5.36%).


Stability and Growth of Payments

Stable Dividend: 569 is not paying a notable dividend for the SG market, therefore no need to check if payments are stable.

Growing Dividend: 569 is not paying a notable dividend for the SG market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 569 is not paying a notable dividend for the SG market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 569's dividend in 3 years as they are not forecast to pay a notable one for the SG market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Liang Cheng (65 yo)

6yrs

Tenure

Mr. Liang Cheng has been Group Chief Executive Officer of Vicplas International Ltd since November 1, 2018 having served as its Acting Chief Executive Officer since October 31, 2014 and also is responsibl ...


Leadership Team

NamePositionTenureCompensationOwnership
Liang Cheng
Group Chief Executive Officer6yrsno data4.72%
SGD 7.5m
Ying Hui Gan
Chief Financial Officer4.5yrsno datano data
Hsheng Cheng
Group Operations Director5.5yrsno datano data
Chin Liang Toon
Technical Director5.42yrsno datano data
Walter Tarca
President of Medical Devices Segment4.75yrsno datano data
Siew Peng Au
Company Secretary8.58yrsno datano data

5.5yrs

Average Tenure

43yo

Average Age

Experienced Management: 569's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Cher Yan Ng
Non-Executive Independent Director10.42yrsno data0.63%
SGD 1.0m
Jane Rose Philomene Gaines-Cooper
Non-Executive Director3.92yrsno data0.98%
SGD 1.6m
Wico Yeo
Non-Executive Independent Chairman11.08yrsno data1.97%
SGD 3.2m
Christopher Paul Lee
Non-Executive Director7yrsno data0.59%
SGD 945.0k

8.7yrs

Average Tenure

59yo

Average Age

Experienced Board: 569's board of directors are considered experienced (8.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vicplas International Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vicplas International Ltd
  • Ticker: 569
  • Exchange: SGX
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: S$160.057m
  • Shares outstanding: 508.12m
  • Website: https://www.vicplas.com

Location

  • Vicplas International Ltd
  • 35 Joo Koon Circle
  • Singapore
  • 629110
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
569SGX (Singapore Exchange)YesOrdinary SharesSGSGDApr 1999

Biography

Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, and China. It manufactures and distributes piping sy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 12:49
End of Day Share Price2020/10/21 00:00
Earnings2020/07/31
Annual Earnings2020/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.